TherapeuticsMD, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-569.0K | $-2.2M | $-10.3M | $112.0M | $-172.4M | $-183.5M | $-176.1M | $-132.6M |
| Depreciation & Amortization | $384.0K | $509.0K | $922.0K | $1.2M | $736.0K | $4.1M | $1.4M | $293.9K |
| Depreciation | — | — | $100.0K | $600.0K | $400.0K | $800.0K | $400.0K | $181.4K |
| Amortization | $176.0K | $1.3M | $483.5K | — | — | $269.5K | $197.6K | $112.5K |
| Stock-Based Compensation | $75.0K | $264.0K | $1.3M | $11.6M | $18.1M | $10.7M | $10.7M | $8.7M |
| Net Cash from Operating Activities | $2.5M | $1.2M | $-23.1M | $9.4M | $-142.7M | $-159.5M | $-165.7M | $-106.8M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | $34.0K | $207.0K | $2.5M | $217.0K |
| Business Acquisitions | $140.0M | $140.0M | $140.0M | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | $-2.2M | $-1.6M | $-23.9M | $-21.5M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | — | $3.2M | — | $129.6M | $80.7M | $188.8M | $162.8M |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | $-142.7M | $-159.7M | $-168.2M | $-107.0M |